Previous 10 | Next 10 |
2023-03-29 07:08:53 ET Biomea Fusion ( NASDAQ: BMEA ) has commenced an underwritten public offering of $125M of common shares. Underwriters have a 30-day option to purchase up to an additional $18.75M of common shares. BMEA -2.5% premarket to $29.94 Source: Press...
2023-03-29 06:59:55 ET Listen on the go! Subscribe to Wall Street Breakfast on Apple Podcasts and Spotify Biomea ( BMEA ) climbs on Phase 2 data for Type 2 diabetes candidate . Ermotti returns as UBS ( UBS ) CEO t o guide Credit Suisse ( CS ...
REDWOOD CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defin...
2023-03-28 17:04:06 ET Biomea Fusion press release ( NASDAQ: BMEA ): Q4 GAAP EPS of -$0.86. As of December 31, 2022, the Company had cash, cash equivalents, restricted cash, and investments of $113.4 million, Biomea reported a net loss attributable to common stockholde...
Expanded clinical development footprint of BMF-219, the company’s lead investigational, orally administered, covalent menin inhibitor, to eight liquid and solid tumor indications and type 2 diabetes across three ongoing clinical trials COVALENT-101 (Phase I study) enrolling four liquid...
2023-03-28 13:10:56 ET Gainers: Biomea Fusion ( BMEA ) +73% . Oscar Health ( OSCR ) +72% . Viking Therapeutics ( VKTX ) +63% . Pyxis Oncology ( PYXS ) +46% . Bird Global ( BRDS ) +44% . NaaS Technology ( NAAS ) +26% ....
2023-03-28 10:00:38 ET Gainers: Biomea Fusion ( BMEA ) +56% . Oscar Health ( OSCR ) +54% . Viking Therapeutics ( VKTX ) +51% . Intra-Cellular Therapies ( ITCI ) +20% . Guardion Health Sciences ( GHSI ) +17% . Losers...
2023-03-28 09:57:25 ET Biomea Fusion ( NASDAQ: BMEA ) added ~57% in the morning hours on Tuesday after announcing that 89% in its Phase 2 trial for lead asset BMF-219 in Type 2 diabetes indicated a decline in blood glucose levels after four weeks of therapy. The readout ...
In Cohort 3, after 4 weeks of once-daily 100 mg dosing with the investigational, oral covalent menin inhibitor, BMF-219, 89% of patients achieved a reduction in A1c, 78% of patients achieved at least a 0.5% reduction in A1c, and 56% achieved at least a 1% reduction in A1c. Initial observation...
REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defin...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-18 04:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA). Investors who purchased Biomea securities are encouraged to obtain additional information...